GRAIL, Inc. (GRAL) Stock

Healthcare · Diagnostics & Research · Member of Other US Stocks

GRAIL, Inc. (GRAL) closed at USD 135.46 on 2026-10-15, a change of +59 % over the past year, with a market capitalization of USD 5.26B.

GRAIL, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

GRAIL, Inc. key figures

Previous close

USD 135.46 (2026-10-15)

1-year change

+59 %

Market cap

USD 5.26B

Enterprise value

USD 4.49B

P/E ratio (trailing)

-12.15

P/E ratio (forward)

-14.28

EPS (trailing)

-9.70

EPS (forward)

-8.25

PEG ratio

n/a

Price to book

2.07

Revenue growth

25.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.06

Employees

910

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About GRAIL, Inc.

GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for GRAIL, Inc. and compare it with other stocks.